10 Numbers to Focus On When Canopy Growth Reports Its Fourth-Quarter Results

Sure, earnings season may have passed for the lion’s share of brand-name companies, but that doesn’t mean earnings reports cease altogether. Next week, the biggest name in all of cannabis, Canopy

Read more »

3 Scenarios That Would Make Aurora Cannabis a Buy

Aurora Cannabis (NYSE:ACB) is the second-largest marijuana stock by market cap, is projected to lead all growers in peak annual output with at least 662,000 kilos, based on company estimates

Read more »

Why Tilray Stock Is Soaring Today?

What happened Shares of Tilray (NASDAQ:TLRY) were trading 19.7% higher as of 11:42 a.m. EDT Monday. The Canadian cannabis producer announced that it had signed a non-binding letter of intent

Read more »

5 Marijuana Stocks for the Perfect “Pot-Folio”

Although the past five weeks have been a rough go for marijuana stocks, the legal cannabis industry has been virtually unstoppable for years. We’ve witnessed Canada become the first industrialized

Read more »

3 Pot Stocks to Avoid Like the Plague in June

After months of sizzling gains, marijuana stocks cooled off in a big way in May. The Horizons Marijuana Life Sciences ETF, the first tradable cannabis ETF that holds more than

Read more »

This Just In: Cronos Group Stock Upgraded

Every day, Wall Street analysts upgrade some stocks, downgrade others, and “initiate coverage” on a few more. But do these analysts even know what they’re talking about? Today, we’re taking

Read more »

How to Invest in Marijuana Stocks the Right Way

If Abigail Van Buren and Ann Landers had teamed up and become personal finance and investing experts — and if they’d kept working into the podcast era — one can

Read more »

Is Aphria a Buy?

Canada’s third largest pot producer, Aphria (NYSE:APHA), has turned into a battleground stock this year. While the company has started to attract a few ardent supporters on Wall Street, such as investment firm

Read more »

3 Marijuana Stocks That Are Cheaper Than Aphria

Late last week, Wall Street investment firm Jefferies initiated coverage on embattled marijuana stock Aphria (NYSE:APHA) with a buy rating and a price target of 15 Canadian dollars ($11.10), implying

Read more »

What to Expect From the FDA’s CBD Hearing

Clear as mud. That’s pretty much the status of cannabidiol (CBD) products in the United States after the 2018 Farm Bill was signed into law in December. Although the bill

Read more »